ClinicalTrials.gg
CompletedNCT04731753Updated Jul 20, 2022

PMCF Study to Examine the Debridement Pad Cutimed DebriClean

An observational study in Wound, sponsored by BSN Medical GmbH. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-20.

Sponsored by BSN Medical GmbH · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
62
Ages
18 Years and older
Sex
All
01

Study summary

Documentation of the performance and safety of the debridement pad Cutimed DebriClean in daily clinical practice

Read the detailed description

60 subjects with superficial wounds in need of debridement will undergo mechanical debridement with the study product.

Per subject, one application of the study product will be documented including photo documentation of the wound and evaluation of the wound bed condition and wound size before and after the debridement.

02

Conditions studied

  • Wound

Browse trials for

Keywords

  • Debridement
03

In context

Wounds and Injuries

2,221 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's enrollment of 62 is below the median of 169 across 690 observational studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

BSN Medical GmbH is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with superficial wounds in need of debridement, for example diabetic ulcers, venous and arterial ulcers, pressure sores, postoperative wounds and wounds healing by secondary intention, superficial burns, the absorption of exudate, slough and dry skin flakes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18 years or older with full legal competence
  • Signed
  • Subjects with wounds in need of debridement, especially diabetic ulcers, venous and arterial ulcers, pressure sores, postoperative wounds and wounds healing by secondary intention, superficial burns
  • Superficial wound
  • Minimum 30 % of the wound is covered by debris, necrosis or slough
  • Wound size > 4 cm²

Exclusion criteria

Exclusion Criteria:

  • Subjects not willing to participate or to attend the scheduled study visit
  • Known sensitivity or allergy to the product components
  • Severe pain or hyperaesthesia in the wound area
  • Patients who are pregnant or lactating
  • Drug abuse or alcohol abuse
  • Patients who participate in any other clinical study investigating drugs or medical devices
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
62 participants (actual)
Patient registry
No

Groups and cohorts

  • Group treated with study product

    Subjects will undergo one mechanical debridement procedure with Cutimed DebriClean

    Device: mechanical debridement

Interventions

  • Devicemechanical debridement

    The mechanical debridement is performed using the debridement pad Cutimed DebriClean. After the pad is moistened with wound-cleansing solution, the wound is cleaned using circular movements while applying gentle pressure.

06

What researchers measure

Primary outcomes

  1. Change of wound bed condition from baseline to assessment immediately after the mechanical debridement (within one study visit)

    Percentage of wound coverage with debris/necrosis/slough Wound edge cleaned smooth Surrounding skin cleaned e.g. from skin flakes

    Time frame: assessed immediately before and immediately after the mechanical debridement (within one study visit)

Secondary outcomes

  1. Wound size after and before wound debridement

    Wound length and wound width are measured using a wound ruler. Wound size is calculated using the formula A = length x width x π/4.

    Time frame: assessed immediately before and immediately after the mechanical debridement (within one study visit)

  2. Time needed for the debridement procedure

    Time from start to completion of the debridement procedure in minutes

    Time frame: Time is measured during the debridement procedure

  3. Debris/necrosis/slough absorbed by test product

    assessed by the investigator (five categories)

    Time frame: assessed immediately after the mechanical debridement

  4. Structural integrity of the test product

    assessed by the investigator (e.g. change in shape, loosening of fibers, ...)

    Time frame: assessed immediately after the mechanical debridement

  5. Pain during the debridement procedure

    Patient reported pain assessed using a visual analogue scale. If applicable, duration of pain is documented.

    Time frame: assessed immediately after the debridement procedure

  6. Adverse device effects

    Discomfort, pressure, burning sensation, bleeding, and irritation of the periwound skin during or after the mechanical debridement, other adverse device effects swelling; redness

    Time frame: assessed immediately after the debridement procedure

07

Study locations

3 sites
  • Praxis am Stadtpark
    Ahlen, Nordrhein-Westfalen 59227, Germany
  • Universitäres Herz- und Gefäßzentrum, Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20251, Germany
  • Pinderfields Hospital
    Wakefield, West Yorkshire WF1 3DG, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — No IPD will be shared. Data are needed for post market clinical follow up.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in May 2022, 13 months.

Of 47 industry-sponsored observational studies under Wounds and Injuries, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 63. This study's 13 months is below that.

Counting every sponsor, half of 312 studies reached it within 28 months; a quarter within 12 and three quarters within 60.

Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Feb 1, 2021
StartActual
Apr 27, 2021
Primary completionActual
May 30, 2022
CompletionActual
May 30, 2022
Last update
Jul 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04731753
Lead sponsor
BSN Medical GmbH
Responsible party
Sponsor
First posted
Feb 1, 2021
Start date
Apr 27, 2021
Primary completion
May 30, 2022
Completion
May 30, 2022
Last update
Jul 20, 2022

Study contacts

Leanne Atkin, Dr.
principal investigator · The University of Huddersfield

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion